Xbrane Refiles Ranibizumab With US FDA

Firm Is Eyeing H1 2024 Approval For US Biosimilar Rival To Lucentis

Xbrane has resubmitted its filing for a ranibizumab biosimilar version of Lucentis to the FDA, suggesting that it could receive approval in the first half of next year.

Sign outside of FDA's headquarters in White Oak, MD
Xbrane’s ranibizumab filing is once again with the FDA • Source: Alamy

Almost a year after having its filing for a Lucentis (ranibizumab) biosimilar knocked back by the US Food and Drug Administration, Xbrane Biopharma has resubmitted the biologics license application to the US regulator.

Last May, the Swedish firm announced that it had withdrawn its BLA after receiving feedback from the FDA that “complementary...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

Biocon Biologics ‘Strategically’ Expands Enbrel Biosimilar With A Launch In Australia

 

After acquiring a solid biosimilars business from Viatris, Biocon Biologics has ticked off another market for its Nepexto (etanercept).

‘Europe Has To Make Up Its Mind’ – Medicines For Europe’s Sieger On The Path Ahead

 
• By 

At an eventful time for the European generics and biosimilars industry, Medicines for Europe interim president and Polpharma CEO Markus Sieger talks about what the European healthcare sector needs and what the off-patent sector can deliver.

Regulatory Recap: FDA Starts ‘Radical Transparency’ Era After Publishing Over 200 CRLs

 

Generics Bulletin reviews global regulatory developments across the world.

Industry Welcomes Support From UK Life Sciences Plan

 
• By 

A new life sciences strategy unveiled by the UK government has won plaudits from the off-patent industry for its inclusion of measures specifically geared towards generics and biosimilars – especially a £1bn savings target linked to biosimilar uptake.

More from Products

Regulatory Recap: FDA Starts ‘Radical Transparency’ Era After Publishing Over 200 CRLs

 

Generics Bulletin reviews global regulatory developments across the world.

Industry Welcomes Support From UK Life Sciences Plan

 
• By 

A new life sciences strategy unveiled by the UK government has won plaudits from the off-patent industry for its inclusion of measures specifically geared towards generics and biosimilars – especially a £1bn savings target linked to biosimilar uptake.

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.